News
Podcast
Author(s):
Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.
In this episode of The Cutaneous Connection, Bradley Burnam, the founder and CEO of Turn Therapeutics, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of Hexagen technology and its potential in eczema, onychomycosis, and more.
Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at DTEditor@mmhgroup.com.